Impact of Neoadjuvant Chemoimmunotherapy on Surgical Outcomes and Time to Radiation in Triple‑Negative Breast Cancer Por [email protected] Impact of Neoadjuvant Chemoimmunotherapy on Surgical Outcomes and Time to Radiation in Triple‑Negative Breast Cancer Read More »
Final results of RIGHT Choice: Ribociclib plus endocrine therapy vs combination chemotherapy in premenopausal women with clinically aggressive HR+/HER2− advanced breast cancer Por Adson Machado Final results of RIGHT Choice: Ribociclib plus endocrine therapy vs combination chemotherapy in premenopausal women with clinically aggressive HR+/HER2− advanced breast cancer Read More »
Effectiveness of gonadotropin‑releasing hormone agonists for ovarianfunction suppression in premenopausal patients with hormonereceptor‑positive breast cancer: a retrospective single‑centerreal‑world study Por Adson Machado Effectiveness of gonadotropin‑releasing hormone agonists for ovarianfunction suppression in premenopausal patients with hormonereceptor‑positive breast cancer: a retrospective single‑centerreal‑world study Read More »
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3 Por [email protected] Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3 Read More »
Survival After Contralateral Axillary Metastasis in Breast Cancer Por [email protected] Survival After Contralateral Axillary Metastasis in Breast Cancer Read More »
Randomized trials of estrogen‑alone and breast cancer incidence: a meta‑analysis Por [email protected] Randomized trials of estrogen‑alone and breast cancer incidence: a meta‑analysis Read More »
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 tria Por [email protected] 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 tria Read More »
Concordance of HER2 status between core needle biopsy and surgical resection specimens of breast cancer: an analysis focusing on the HER2‑low status Por [email protected] Concordance of HER2 status between core needle biopsy and surgical resection specimens of breast cancer: an analysis focusing on the HER2‑low status Read More »
Outcomes of sentinel node biopsy according to MRI response in an association with the subtypes in cN1–3 breast cancer after neoadjuvant systemic therapy, multicenter cohort study Por [email protected] Outcomes of sentinel node biopsy according to MRI response in an association with the subtypes in cN1–3 breast cancer after neoadjuvant systemic therapy, multicenter cohort study Read More »
Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer Por [email protected] Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer Read More »
Premastectomy Radiotherapy and Immediate Breast Reconstruction Por [email protected] Premastectomy Radiotherapy and Immediate Breast Reconstruction Read More »
Giredestrant for Estrogen Receptor–Positive, HER2- Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study Por [email protected] Giredestrant for Estrogen Receptor–Positive, HER2- Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study Read More »
